RecruitingNCT07004582

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Preclinical ex Vivo Patient-derived 3D Cultures for the Prediction of Prostate Cancer Treatment Response


Sponsor

Maastricht Radiation Oncology

Enrollment

600 participants

Start Date

Mar 15, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria3

  • Patients aged 18 years or older
  • Patients with prostate cancer
  • Patients planned for HDR brachytherapy treatment for high-risk or recurrent prostate cancer or transperineal prostate biopsy with MRI-suspected metastatic prostate cancer with at least clinical stage T3-4.

Exclusion Criteria2

  • Patients younger than 18 years
  • Patients of whom it is not possible to obtain left-over tissue as part of the normal clinical treatment procedure (e.g., if all tumor material is required for the pathologist to make a diagnosis, to stage the patient or to perform a molecular diagnosis).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHDR brachytherapy

High dose rate (HDR) brachytherapy for the treatment of high-risk or recurrent prostate cancer

DIAGNOSTIC_TESTDiagnostic biopsy

Transperineal prostate biopsies guided with transrectal ultrasound for the diagnosis of (recurrent) prostate cancer


Locations(3)

Zuyderland Medisch Centrum

Heerlen, Limburg, Netherlands

Academisch Ziekenhuis Maastricht

Maastricht, Limburg, Netherlands

Maastricht Radiation Oncology

Maastricht, Limburg, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07004582


Related Trials